Expanded Access of Onvansertib With FOLFIRI and Bevacizumab for the Second-Line Treatment of Participants With KRAS-Mutated Metastatic Colorectal Cancer

ABSTRACT: This is an expanded access program for eligible participants designed to provide access to onvansertib in combination with FOLFIRI and bevacizumab.

DISEASE(S): Kras Gene Mutation,Metastatic Colorectal Cancer,Colorectal Cancer,Colorectal Neoplasms

PROVIDER: 2343718 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR